Corton Capital’s Novavax NVAX Stock Holding History

Corton Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,505	Closed	-$323K	–	607
2024 Q2	$323K	Buy	+25,505	New	+$257K	0.17%	170

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corton Capital's NVAX Position: Q3 2024 in Review

Corton Capital sold out of Novavax (NVAX) in Q3 2024, closing a stake of 25,505 shares — an estimated $323K sold.

Corton Capital first reported a position in NVAX in Q2 2024 and held it in 1 quarter. The position peaked at $323K in Q2 2024. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Corton Capital reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Corton Capital sold 25,505 Novavax shares in Q3 2024, an estimated $323K.
Corton Capital first reported a position in Novavax in Q2 2024 and held it in 1 quarter.
Corton Capital's Novavax position peaked at $323K in Q2 2024.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Corton Capital's 13F filing for Q3 2024, filed 14 Nov 2024.